Antares Pharma, Inc. (ATRS)
| Market Cap | 674.33M |
| Revenue (ttm) | 149.60M |
| Net Income (ttm) | 56.20M |
| Shares Out | 166.07M |
| EPS (ttm) | 0.33 |
| PE Ratio | 12.15 |
| Forward PE | 15.75 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $4.01 |
| Previous Close | $4.13 |
| Change ($) | -0.12 |
| Change (%) | -2.91% |
| Day's Open | 4.16 |
| Day's Range | 3.97 - 4.17 |
| Day's Volume | 734,641 |
| 52-Week Range | 2.39 - 5.07 |
In my opinion, choosing U.S.-listed securities that have the following characteristics represents a solid starting point when looking for potential value opportunities:
Antares Pharma (ATRS) delivered earnings and revenue surprises of -25.00% and 7.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Antares Pharma (NASDAQ:ATRS) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share were flat 0.00% over the past year to $0.03, which were in line with the...
EWING, N.J., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executi...
EWING, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced it will release its fourth quarter and full-year ...
EWING, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executi...
These interesting low-cost stocks have the opportunity to grow.
These companies offer more potential than the stock price might indicate.
EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executi...
EWING, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executi...
Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q3 2020 Results - Earnings Call Transcript
Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and 10.84%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EWING, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced it will release its third quarter 2020 financial ...
Since my last article in July, Antares has rallied over 20%, finally getting back to the lower end of where it was trading pre-COVID-19.
Antares Pharma Enters Exclusive License Agreement With Ferring Pharmaceuticals for Nocdurna® in U.S.
Antares Expands Urology Portfolio and Leverages Commercial Organization Antares Expands Urology Portfolio and Leverages Commercial Organization
EWING, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Exec...
Jack Howarth Retires as Vice President of Corporate Affairs Jack Howarth Retires as Vice President of Corporate Affairs
Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q2 2020 Results - Earnings Call Transcript
Antares Pharma (NASDAQ: ATRS) shares are trading higher on Monday after the company announced a deal with Lunatus Global to distribute and promote XYOSTED in Saudi Arabia.
EWING, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced they have entered into an exclusive distribution agreement with...
EWING, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”), a pharmaceutical technology company, announced the first commercialization of the Compan...
EWING, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced the appointment of Patrick Shea to the position...
Antares Continues To Quietly Grow Revenue
EWING, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ray...
Why is a fast-growing company making one of the best testosterone replacement therapies on the market so underappreciated by investors?
Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q1 2020 Results - Earnings Call Transcript
First-quarter financial results failed to spark investors' animal spirits.
Antares Pharma: An Undervalued Stock To Buy During The COVID-19 Crisis
Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q4 2019 Results - Earnings Call Transcript
Products from the pharmaceutical technology company continued to pick up momentum in the fourth quarter.
Antares Pharma: Reasonable Expectations For 2020
Antares Pharma: XYOSTED's Prescription Growth Is Running On All Cylinders
The Company Expects 2019 Net Revenue at Upper End or Exceed Range of $115 - $120 Million Guidance The Company Expects 2019 Net Revenue at Upper End or Exceed Range of $115 - $120 Million Guidance
Investors are locking in gains in this fast-growing drugmaker.
EWING, N.J., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Edward Tykot to the position of Senior Vice President, Corporate Development. Mr. ...
EWING, N.J., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”) today announced that the Company’s social media campaign for XYOSTED®, has been honored w...
Antares' Xyosted Is One Of The Best Testosterone Replacement Therapies Available
Novel Drug Device Combination Product To Be Developed For The Treatment Of Suspected Acute Myocardial Infarction Novel Drug Device Combination Product To Be Developed For The Treatment Of Suspected Acut...
Novel Drug Device Combination Product To Be Developed For The Treatment Of Suspected Acute Myocardial Infarction Novel Drug Device Combination Product To Be Developed For The Treatment Of Suspected Acut...
EWING, N.J., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares” or “Company”) today announced that it has received the final payment of $2.5 million from Ferring Pharmace...
EWING, N.J., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that data from two poster presentations will be presented on Saturday October 26, 2019 at the 20th An...
EWING, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg Thalmann ...
Every 1% of market share captured by XYOSTED in the testosterone replacement therapy market would grant ATRS $8.5 million in annual sales.
Since the approval of Clarus' TRT drug Jatenzo on March 28, Antares shares have been under pressure, breaking an upward trend to the downside.
Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q1 2019 Results - Earnings Call Transcript
Regardless of the company’s growing, diversified portfolio and pipeline of drugs, Antares stock continues to trade like it is a one-product company.
About ATRS
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active r... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Oct 2, 1996 |
| CEO Robert Apple | Employees 185 |
| Stock Exchange NASDAQ | Ticker Symbol ATRS |
Analyst Forecasts
According to 6 analysts, the average rating for Antares Pharma stock is "Strong Buy." The 12-month stock price forecast is 6.42, which is an increase of 60.10% from the latest price.